Dr. Cora Sternberg on Mutation Status as a Treatment Driver in Advanced Prostate Cancer

Cora N. Sternberg, MD, Medical Oncologist at Weill Cornell Medicine and New York-Presbyterian Hospital, opines on the importance of mutation status in advanced prostate cancer and whether all patients should receive germline and somatic testing.

While it is unclear whether genomic research is needed to select patients for treatment, Dr. Sternberg believes it is crucial to do so. “I think that mutation status is important in advanced prostate cancer and we should be doing both germline and somatic testing on our patients,” she says. PARP inhibitors have demonstrated effectiveness for patients with BRCA1/2 mutations, and perhaps in an unselected population, though this is yet to be determined in the latter.

View Dr. Sternberg’s other comments on Imaging and Treatment Changes for nmCRPC.